Oculis Holding AG (NASDAQ:OCS) Short Interest Up 105.6% in December

Oculis Holding AG (NASDAQ:OCS) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 101,167 shares, a growth of 105.6% from the November 30th total of 49,197 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 95,845 shares, the short-interest ratio is currently 1.1 days. Based on an average daily volume of 95,845 shares, the short-interest ratio is currently 1.1 days. Approximately 0.2% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on OCS shares. Stifel Nicolaus lifted their target price on Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. JPMorgan Chase & Co. initiated coverage on Oculis in a research report on Friday, December 19th. They issued an “overweight” rating and a $38.00 price objective for the company. HC Wainwright boosted their price objective on Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Needham & Company LLC restated a “buy” rating and issued a $36.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Finally, Bank of America decreased their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Oculis currently has an average rating of “Moderate Buy” and an average price target of $41.50.

Oculis Price Performance

Shares of OCS traded down $0.19 during mid-day trading on Friday, reaching $20.50. The company had a trading volume of 59,056 shares, compared to its average volume of 111,721. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The company has a market capitalization of $1.07 billion, a P/E ratio of -8.13 and a beta of 0.32. Oculis has a twelve month low of $14.00 and a twelve month high of $23.08. The company’s 50-day moving average is $20.00 and its 200-day moving average is $18.90.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. On average, equities analysts anticipate that Oculis will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bosun Asset Management LLC bought a new stake in Oculis during the second quarter worth about $378,000. Marshall Wace LLP acquired a new stake in Oculis during the 2nd quarter valued at $393,000. Geode Capital Management LLC raised its position in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares during the last quarter. Bank of America Corp DE boosted its stake in Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares in the last quarter. Finally, Woodline Partners LP grew its holdings in shares of Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares during the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.